Rhythm Pharmaceuticals announced that the Italian Medicine Agency, AIFA, approved reimbursement for IMCIVREE for the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome, BBS. “We are pleased that AIFA has recognized the need for a precision medicine for obesity and control of hunger in BBS,” said Yann Mazabraud, Executive Vice President and Head of International at Rhythm. “Now families in Italy who are affected by this rare neuroendocrine disease will be able to access the first and only treatment option authorized in the European Union, and we look forward to working with the community in Italy to deliver IMCIVREE to patients as we aim to expand access in Europe country-by-country.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RYTM:
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
- Biotech Alert: Searches spiking for these stocks today
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals price target raised to $49 from $31 at BofA
- Rhythm announces global licensing agreement with LG Chem for LB54640